Does Medicare Part D Cover GLP-1 Weight Loss Medications?

You have spent decades managing your weight. You have tried diets, exercise programs, and behavioral approaches. Now, at 68, your provider mentions a GLP-1 medication that might finally help. But when you check your Medicare Part D plan, you find the medication is not covered. That can feel like one more door closing.

Here is what is actually happening with Medicare and GLP-1 weight loss medications, and what your real options are.

Transformation Health is an independent guide, not a provider: we do not prescribe, sell medication, or bill insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.

The Medicare Part D Weight Loss Drug Exclusion

Medicare Part D, the prescription drug coverage part of Medicare, has a specific rule written into law. When Congress created Part D in the Medicare Modernization Act of 2003, it left out a list of drug categories that state Medicaid programs may exclude, and one of them is “agents when used for anorexia, weight loss, or weight gain."^[1][2]

The exclusion was written long before GLP-1 medications were approved for weight management. It is tied to how a drug is used, not to the drug itself.

This exclusion applies when a medication is prescribed for weight management alone. CMS says Medicare and Medicaid currently generally do not cover these drugs for the weight loss indication.^[4] As of 2026-10-16, the exclusion is still in the statute.^[1][2]

When GLP-1 Is Actually Covered by Medicare Part D

Medicare Part D coverage gets clearer when a GLP-1 medication is prescribed for a condition other than weight loss alone. As of 2026-10-16, CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea, and certain metabolic dysfunction-associated steatohepatitis (MASH) uses as eligible for Part D coverage.^[5]

Type 2 Diabetes: Part D plans may cover GLP-1 medications when prescribed for type 2 diabetes. If you have type 2 diabetes and your provider prescribes a GLP-1 medication approved by the FDA for diabetes, that is the indication your provider documents.

However, coverage is plan-specific. Your specific Medicare Part D plan may have the medication on its formulary at a certain tier (which affects your cost-sharing). Many plans require prior authorization, meaning your provider must request approval from the plan before the pharmacy can dispense the medication. Your cost depends on your plan’s tier structure and whether you have met your deductible.

Check your Medicare plan’s formulary directly or call the plan to see if the specific GLP-1 medication you need is covered, what tier it sits on, and what prior authorization is required.

What Changed in 2024 and 2025, and What’s Coming in 2026-2027

FDA Approval for Cardiovascular Risk Reduction (2024)

In March 2024, the FDA approved Wegovy (semaglutide injection), with diet and physical activity, to reduce the risk of major adverse cardiovascular events (cardiovascular death, heart attack, or stroke) in adults with established cardiovascular disease and either obesity or overweight.^[6] The approval was based on the SELECT trial^[8], in which adults with established cardiovascular disease and overweight or obesity, but without diabetes, who took semaglutide 2.4 mg had about a 20% lower risk of those events than people who took placebo. Results vary. Trial results describe study participants and are not a prediction for any individual.

The Wegovy label carries a boxed warning about the risk of thyroid C-cell tumors, and common side effects include nausea, diarrhea, vomiting, and constipation. Review the full prescribing information with your provider.^[6]

This change matters for Medicare coverage. Because cardiovascular risk reduction is a use other than weight loss, the statutory weight loss exclusion does not apply to it. As of 2026-10-16, CMS says people prescribed Wegovy for this cardiovascular use should continue to get coverage through Part D, not through the GLP-1 Bridge.^[5]

In practical terms, a Medicare beneficiary with established cardiovascular disease (such as a prior heart attack or stroke, or coronary artery disease) may have a path to coverage if their provider prescribes Wegovy for cardiovascular risk reduction. The prescription and documentation need to reflect that indication.

The same logic applies to Zepbound, which is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity; CMS lists that use as eligible for Part D coverage.^[5][7] The Zepbound label also carries a boxed warning about thyroid C-cell tumors.^[7]

This is still plan-specific and still requires documentation. Your provider would need to note in the medical record what the prescription is for, your plan would need to cover that indication, and you would need to meet your plan’s other requirements (formulary, tier, prior authorization).

The Medicare GLP-1 Bridge and the BALANCE Model (2026-2027)

The Medicare GLP-1 Bridge: CMS is running a short-term demonstration, the Medicare GLP-1 Bridge, that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs used for weight management between July 1, 2026 and December 31, 2027. It operates outside the Part D benefit’s coverage and payment flow, so it does not change the statutory exclusion.^[3] As of 2026-10-16, the CMS page lists a flat copay, notes that the Part D deductible does not apply, and says the low-income subsidy does not reduce it.^[3] People prescribed a GLP-1 for a use Part D already covers (such as type 2 diabetes) are not eligible for the Bridge.^[5] Eligibility criteria and covered products are set by CMS and can change, so check the CMS page or call 1-800-MEDICARE before you count on it.

The BALANCE Model in Medicare: As of 2026-10-16, CMS says the BALANCE Model is not expected to launch in Medicare in 2027. The Bridge lets CMS collect GLP-1 use data ahead of any potential BALANCE implementation in Part D.^[4] Do not plan around a Medicare start date until CMS announces one.

Pending legislation: Bills to let Medicare cover anti-obesity medications have been proposed, but as of 2026-10-16 the exclusion is still in the statute.^[1][2] Coverage should not be assumed based on pending legislation.

Medicare Advantage and Plan Variation

If you have Medicare Advantage (Part C) instead of Original Medicare with a separate Part D plan, your coverage rules may be different.

Medicare Advantage plans are private insurance plans that cover Part A and Part B benefits and often include prescription drug coverage. Federal rules let drug plans that offer enhanced alternative coverage add supplemental benefits, which can include drugs that are excluded from basic Part D coverage.^[9] Whether a given plan does this is up to the plan.

If you have a Medicare Advantage plan with prescription drug coverage, or a stand-alone Part D plan, check your plan’s formulary and extra benefits section.

Call your plan directly and ask whether GLP-1 medications for weight management are covered as a supplemental benefit.

What to Do If You Cannot Access Medicare Coverage

You have several paths if your Medicare plan does not cover GLP-1 for your situation.

First, confirm your situation: Check with your provider and your Part D or Medicare Advantage plan about whether you have type 2 diabetes, established cardiovascular disease, or moderate to severe obstructive sleep apnea, since each is a use CMS lists as eligible for Part D coverage.^[5] If none of these has been diagnosed or documented, ask your provider whether any of them applies to you.

If you have type 2 diabetes: Work with your provider to request prior authorization for a GLP-1 medication from your plan. Different plans have different approval processes, and some medications are covered on certain tiers. Your provider’s office usually handles prior authorization, and decisions can take days to weeks depending on the plan.

If you do not have one of those conditions: Part D generally will not cover a GLP-1 for weight loss alone. Check whether you are eligible for the Medicare GLP-1 Bridge through CMS or 1-800-MEDICARE.^[3] Paying out of pocket is another option.

Consider cash-pay options: Some telehealth programs and some manufacturers’ self-pay options do not go through insurance, so there is no prior authorization step. You pay the full cost out of pocket, and a licensed provider still decides whether a prescription is appropriate. Prices vary by program and dose, so compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. Many cash-pay programs prescribe compounded semaglutide or tirzepatide.

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.^[10] Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency.

Transformation Health does not accept payment from providers. How we make money.

Using HSA Funds on Medicare

There is a common misconception about HSAs and Medicare that deserves clarification.

Once you enroll in Medicare, you can no longer make contributions to a health savings account. The IRS says that beginning with the first month you are enrolled in Medicare, your contribution limit is zero, and that applies to retroactive Medicare coverage too.^[11]

However, if you already have money in an HSA before enrolling in Medicare, distributions used for qualified medical expenses are generally tax-free.^[11] The funds do not disappear or become inaccessible just because you are on Medicare. You simply cannot add new money to the account.

Whether a specific medication or service counts as a qualified medical expense depends on IRS rules and your situation. Check with your HSA plan administrator or a tax advisor.

Your Next Steps

If you are a Medicare beneficiary interested in GLP-1 weight loss treatment, here is what to do:

1. Check your coverage status: Contact your Medicare Part D or Medicare Advantage plan and ask whether GLP-1 medications are covered for your specific situation. If you have type 2 diabetes, ask about coverage under that indication. If you have cardiovascular disease, ask about coverage under the cardiovascular risk reduction indication. If you have obstructive sleep apnea, ask about that indication. Get specific information about formulary status, coverage tier, prior authorization requirements, and typical cost-sharing.

2. Talk to your provider: Tell your provider you are interested in GLP-1 treatment. If you have diabetes, your provider can start the authorization process. If you do not have diabetes but have cardiovascular disease or sleep apnea, ask your provider whether one of those indications applies to you.

3. Check the Medicare GLP-1 Bridge: If your only reason for the medication is weight management, check whether you are eligible for the Bridge through CMS or 1-800-MEDICARE.^[3]

4. Evaluate cash-pay options if needed: If your plan does not cover GLP-1, a cash-pay program with a licensed provider may be a realistic option. Compare the total cost and terms, not just the monthly price.

5. Confirm HSA rules (if applicable): If you have an HSA with existing funds, check with your plan administrator about what counts as a qualified medical expense.

Citations

[1] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions). https://www.law.cornell.edu/uscode/text/42/1395w-102

[2] 42 U.S.C. 1396r-8(d)(2)(A) (drugs that may be excluded or restricted: “agents when used for anorexia, weight loss, or weight gain”). https://www.law.cornell.edu/uscode/text/42/1396r-8

[3] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

[4] Centers for Medicare and Medicaid Services. “BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model.” Accessed 2026-10-16. https://www.cms.gov/priorities/innovation/innovation-models/balance

[5] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge: Information for Part D Plans.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans

[6] Novo Nordisk. WEGOVY (semaglutide) prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[7] Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[8] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/

[9] 42 CFR 423.104(f)(1) (enhanced alternative coverage; supplemental benefits). https://www.law.cornell.edu/cfr/text/42/423.104

[10] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

[11] U.S. Internal Revenue Service. “Publication 969: Health Savings Accounts and Other Tax-Favored Health Plans.” Accessed 2026-10-16. https://www.irs.gov/publications/p969